vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and JOINT Corp (JYNT). Click either name above to swap in a different company.
JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $10.7M, roughly 1.4× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 6.5%, a 17.0% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 3.1%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -28.6%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
ABUS vs JYNT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $15.2M |
| Net Profit | $2.5M | $991.1K |
| Gross Margin | — | 81.4% |
| Operating Margin | 13.9% | 4.9% |
| Net Margin | 23.5% | 6.5% |
| Revenue YoY | 522.2% | 3.1% |
| Net Profit YoY | 112.7% | 5510.5% |
| EPS (diluted) | $0.01 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $13.4M | ||
| Q2 25 | $10.7M | $13.3M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | — | $30.2M | ||
| Q2 24 | — | $30.3M | ||
| Q1 24 | — | $29.7M |
| Q4 25 | — | $991.1K | ||
| Q3 25 | — | $855.0K | ||
| Q2 25 | $2.5M | $93.4K | ||
| Q1 25 | — | $967.8K | ||
| Q4 24 | — | $17.7K | ||
| Q3 24 | — | $-3.2M | ||
| Q2 24 | — | $-3.6M | ||
| Q1 24 | — | $947.0K |
| Q4 25 | — | 81.4% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.4% | ||
| Q3 24 | — | 90.7% | ||
| Q2 24 | — | 90.7% | ||
| Q1 24 | — | 90.9% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 13.9% | -8.6% | ||
| Q1 25 | — | -5.2% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | — | -5.9% | ||
| Q1 24 | — | -1.4% |
| Q4 25 | — | 6.5% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | 23.5% | 0.7% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | -10.5% | ||
| Q2 24 | — | -11.9% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | — | $0.06 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | $0.01 | $0.01 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | — | $-0.21 | ||
| Q2 24 | — | $-0.24 | ||
| Q1 24 | — | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $23.6M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $15.1M |
| Total Assets | $103.3M | $61.0M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $23.6M | ||
| Q3 25 | — | $29.7M | ||
| Q2 25 | $37.4M | $29.8M | ||
| Q1 25 | — | $21.9M | ||
| Q4 24 | — | $25.1M | ||
| Q3 24 | — | $20.7M | ||
| Q2 24 | — | $17.5M | ||
| Q1 24 | — | $18.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $15.1M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | $83.0M | $23.2M | ||
| Q1 25 | — | $22.8M | ||
| Q4 24 | — | $20.7M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $23.2M | ||
| Q1 24 | — | $26.2M |
| Q4 25 | — | $61.0M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | $103.3M | $73.2M | ||
| Q1 25 | — | $80.1M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $79.6M | ||
| Q2 24 | — | $82.4M | ||
| Q1 24 | — | $85.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $1.8M |
| Free Cash FlowOCF − Capex | — | $334.7K |
| FCF MarginFCF / Revenue | — | 2.2% |
| Capex IntensityCapex / Revenue | 0.0% | 9.9% |
| Cash ConversionOCF / Net Profit | -6.24× | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | $-15.7M | $868.6K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $-973.5K | ||
| Q1 24 | — | $2.8M |
| Q4 25 | — | $334.7K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | $363.6K | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $8.2M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $2.4M |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 10.9% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | -30.8% | ||
| Q4 24 | — | 55.9% | ||
| Q3 24 | — | 10.6% | ||
| Q2 24 | — | -4.1% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | 0.0% | 3.8% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | -6.24× | 9.30× | ||
| Q1 25 | — | -3.82× | ||
| Q4 24 | — | 532.98× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
